EXCLUSIVE: Plus Therapeutics Tells Benzinga 'Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases'
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has announced preliminary safety and efficacy results from a dose escalation trial, which showed a median overall survival of 10 months for patients with leptomeningeal metastases.
August 11, 2023 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The announcement of promising preliminary results from Plus Therapeutics' dose escalation trial could potentially boost investor confidence and positively impact the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence, as they indicate progress and potential success in the company's research and development efforts. This could lead to increased demand for the company's stock, potentially driving up the price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100